Astrazeneca AB has reported new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment covalently linked to cytotoxic drug potentially useful for the treatment of cancer.
A joint Ajax Therapeutics Inc. and Dana-Farber Cancer Institute Inc. patent divulges new JAK2 degradation inducers intended for use in the treatment of polycythemia vera, myeloid leukemia and essential thrombocythemia.
Pfizer Inc. has discovered new gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of type 2 diabetes and obesity.
AN2 Therapeutics Inc. has synthesized boron heterocycle-containing compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors. They are designed for potential use in the treatment of cancer, hypophosphatasia, infections, metabolic, autoimmune and autoinflammatory diseases.
Gilead Sciences Inc. has identified new GTPase KRAS G12D mutant inhibitors and proteolysis targeting chimeras (PROTACS) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS G12D mutant-targeting moiety potentially useful for the treatment of cancer.
Bristol Myers Squibb Co. (BMS) has disclosed new Ikaros family zinc finger protein 1 (IKZF1, Ikaros), IKZF2 (Helios), IKZF3 (Aiolos) and/or IKZF4 (Eos) degradation inducers potentially useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists. As such, they are believed to be potentially useful for the treatment of rheumatoid arthritis, amyotrophic lateral sclerosis, frontotemporal dementia, multiple sclerosis, prion disease, stroke, Parkinson's and Alzheimer's disease.
Pfizer Inc. has patented new gastric inhibitory polypeptide receptor (GIPR) antagonists reported to be potentially useful for the treatment of type 2 diabetes and obesity.
A recent Ensem Therapeutics Inc. patent details the discovery of tricyclic derivatives acting as GTPase KRAS (mutant) inhibitors for use in the treatment of cancer.
RSS